JP7684282B2 - ヒドロキシピロリジン誘導体およびその医薬用途 - Google Patents
ヒドロキシピロリジン誘導体およびその医薬用途 Download PDFInfo
- Publication number
- JP7684282B2 JP7684282B2 JP2022512589A JP2022512589A JP7684282B2 JP 7684282 B2 JP7684282 B2 JP 7684282B2 JP 2022512589 A JP2022512589 A JP 2022512589A JP 2022512589 A JP2022512589 A JP 2022512589A JP 7684282 B2 JP7684282 B2 JP 7684282B2
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- hydroxy
- pyrrolidin
- optionally substituted
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020065410 | 2020-03-31 | ||
| JP2020065410 | 2020-03-31 | ||
| PCT/JP2021/013694 WO2021201036A1 (ja) | 2020-03-31 | 2021-03-30 | ヒドロキシピロリジン誘導体およびその医薬用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2021201036A1 JPWO2021201036A1 (https=) | 2021-10-07 |
| JPWO2021201036A5 JPWO2021201036A5 (https=) | 2024-04-26 |
| JP7684282B2 true JP7684282B2 (ja) | 2025-05-27 |
Family
ID=77927631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022512589A Active JP7684282B2 (ja) | 2020-03-31 | 2021-03-30 | ヒドロキシピロリジン誘導体およびその医薬用途 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230312542A1 (https=) |
| EP (1) | EP4129402A4 (https=) |
| JP (1) | JP7684282B2 (https=) |
| CN (1) | CN115298173A (https=) |
| WO (1) | WO2021201036A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240327392A1 (en) * | 2021-06-25 | 2024-10-03 | Albius Sciences Alpha Private Limited | Heterocycloalkyl-substituted polyheteroazole derivatives as medicaments for treating and/or preventing rs virus infections |
| KR20240148807A (ko) * | 2022-03-22 | 2024-10-11 | 옵쉐스트바 스 아그라니첸너이아트볫스트벤너스찌유 "빅-즈다로비예쥐보트니흐" | 메데토미딘 및 그 유도체의 제조 방법 |
| CN119677735A (zh) * | 2022-05-11 | 2025-03-21 | 基因泰克公司 | 作为vhl配体的苯并噻唑化合物 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019084026A1 (en) | 2017-10-24 | 2019-05-02 | Genentech, Inc. | (4-HYDROXYPYRROLIDIN-2-YL) -HETEROCYCLIC COMPOUNDS AND METHODS OF USE |
| WO2020051564A1 (en) | 2018-09-07 | 2020-03-12 | Arvinas Operations, Inc. | Polycyclic compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2425288A1 (en) | 2000-10-11 | 2002-05-02 | Sander G. Mills | Pyrrolidine modulators of ccr5 chemokine receptor activity |
| AU2006223482A1 (en) | 2005-03-14 | 2006-09-21 | Janssen Pharmaceutica, N.V. | Process for the preparation of opioid modulators |
| EP2238128B1 (en) | 2007-12-26 | 2012-08-22 | Sanofi | Heterocyclic pyrazole-carboxamides as p2y12 antagonists |
| PL2242759T3 (pl) | 2008-02-06 | 2013-06-28 | Astrazeneca Ab | Związki |
| EP2384328B1 (en) | 2008-11-27 | 2013-02-13 | Boehringer Ingelheim International GmbH | 6,7,8,9-tetrahydro-5h-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and process for preparing them |
| US8673954B2 (en) * | 2009-02-27 | 2014-03-18 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
| EA020031B1 (ru) * | 2009-06-11 | 2014-08-29 | Эббви Бахамаз Лтд. | Противовирусные соединения |
| AU2010274001A1 (en) * | 2009-07-16 | 2012-02-23 | Vertex Pharmaceuticals Incorporated | Benzimidazole analogues for the treatment or prevention of Flavivirus infections |
| EP2305660A1 (en) | 2009-09-25 | 2011-04-06 | Almirall, S.A. | New thiadiazole derivatives |
| WO2011084402A1 (en) | 2009-12-21 | 2011-07-14 | Merck Sharp & Dohme Corp. | Tyrosine kinase inhibitors |
| EP2752410B1 (en) | 2011-10-25 | 2016-08-31 | Shionogi & Co., Ltd. | Heterocycle derivative having pgd2 receptor antagonist activity |
| KR102668696B1 (ko) * | 2012-01-12 | 2024-05-29 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| US9783527B2 (en) | 2014-09-16 | 2017-10-10 | Abbvie Inc. | Indazole ureas and method of use |
-
2021
- 2021-03-30 JP JP2022512589A patent/JP7684282B2/ja active Active
- 2021-03-30 CN CN202180026438.5A patent/CN115298173A/zh active Pending
- 2021-03-30 US US17/915,794 patent/US20230312542A1/en active Pending
- 2021-03-30 WO PCT/JP2021/013694 patent/WO2021201036A1/ja not_active Ceased
- 2021-03-30 EP EP21778705.0A patent/EP4129402A4/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019084026A1 (en) | 2017-10-24 | 2019-05-02 | Genentech, Inc. | (4-HYDROXYPYRROLIDIN-2-YL) -HETEROCYCLIC COMPOUNDS AND METHODS OF USE |
| WO2020051564A1 (en) | 2018-09-07 | 2020-03-12 | Arvinas Operations, Inc. | Polycyclic compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115298173A (zh) | 2022-11-04 |
| EP4129402A4 (en) | 2024-06-12 |
| JPWO2021201036A1 (https=) | 2021-10-07 |
| EP4129402A1 (en) | 2023-02-08 |
| US20230312542A1 (en) | 2023-10-05 |
| WO2021201036A1 (ja) | 2021-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7772778B2 (ja) | 縮合環を有するｇｌｐ－１受容体作動薬を含有する医薬組成物 | |
| CN113501821B (zh) | 具有mgat-2抑制活性的稠合环衍生物 | |
| JP7684282B2 (ja) | ヒドロキシピロリジン誘導体およびその医薬用途 | |
| DK2455381T5 (en) | Triazolopyridinforbindelse and its effect as an inhibitor of prolyl hydroxylase and induce erythropoietin production by | |
| CA2781660C (en) | Indole compound and pharmaceutical use thereof | |
| JP6618120B2 (ja) | ＴｒｋＡ阻害活性を有する複素環および炭素環誘導体 | |
| CA2897843C (en) | Pyrazolopyrimidine compounds | |
| JP5806417B2 (ja) | Ｍｇａｔ２阻害剤としてのアリールジヒドロピリジノンおよびピペリジノン | |
| CA2957046C (en) | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases | |
| KR102633911B1 (ko) | 9원 축합환 유도체 | |
| CA2899088A1 (en) | Thiazole and oxazole compounds as glycosidase inhibitors | |
| KR102291444B1 (ko) | 디히드로피리디논 mgat2 억제제 | |
| EP4110781B1 (en) | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| KR20110117215A (ko) | ５-원 헤테로시클릭 화합물의 아자스피라닐-알킬카르바메이트의 유도체, 그의 제조법, 및 그의 치료 용도 | |
| CN114340616A (zh) | 作为食欲肽拮抗剂的吡唑和咪唑衍生物、组合物以及方法 | |
| JP7015092B2 (ja) | ドーパミンｄ３受容体拮抗作用を有する含窒素縮環化合物 | |
| JP2022534704A (ja) | オレキシンアンタゴニストとしてのイミダゾロ誘導体、組成物、及び方法 | |
| KR102441864B1 (ko) | 괴사의 억제제로서 헤테로아릴 화합물, 이의 조성물 및 이의 용도 | |
| JP7642859B2 (ja) | ヒストン脱アセチル化酵素６阻害剤としての１，３，４－オキサジアゾールチオカルボニル化合物およびこれを含む薬剤学的組成物 | |
| WO2015089137A1 (en) | Acylguanidines as tryptophan hydroxylase inhibitors | |
| WO2025218831A2 (zh) | 具有ptpn2/ptpn1抑制活性的噻二唑烷酮衍生物及其制备方法和应用 | |
| KR20110101215A (ko) | 시스테인 프로테아제 억제제 | |
| WO2012038904A1 (fr) | Derives de nicotinamide, leur preparation et leur application en therapeutique | |
| CA2663080A1 (fr) | Derives de pyrrolizine, indolizine et quinolizine, leur preparation et leur application en therapeutique. | |
| TWI422585B (zh) | 3,8-diaminotetrahydroquinoline derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240329 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240329 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240416 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20241217 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250128 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20250213 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20250219 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250430 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250515 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7684282 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |